Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

July 28, 2025 - DALLAS People in 15 regions across the U.S. will soon benefit from the American Heart Association's ...

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

Re-Vana Therapeutics partners Boehringer Ingelheim to develop long-acting eye treatments positioning Northern Ireland as a ...

Queen’s University Belfast spin-out company Re-Vana Therapeutics has signed a landmark collaboration deal with German ...

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast ...

A Belfast company Re-Vana Therapeutics – a spin-out from Queen’s University – has signed a major collaboration deal that could be worth more than $1bn.

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...